<div id="readability-page-1"><div> <div> , /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the past year. Continue Reading This year's awards honored the companies and individuals at the forefront of China's dynamic healthcare sector — from landmark licensing and partnership agreements to capital markets milestones and private financings that are reshaping the industry. Award recipients were selected through a formal vote conducted by CHIC's Founders and 2026 Organizing Committee &amp; Working Group, whose collective expertise spans venture capital, private equity, and global healthcare leadership. Award Winners IPO of the YearWinner: Insilico Medicine Accepted by: Leah Liu, VP and Global Head of IR &amp; Capital Markets, Insilico Medicine Presenter: Richard Wang, China Partner, Wilson SonsiniPrivate Financing of the Year — TiedCo-Winner: Kailera Therapeutics Accepted by: Shelley Liu, Head of China Business Development &amp; Strategy, Hengrui (Kailera Therapeutics was built on Hengrui assets) Presenter: Kan Chen, Co-Head of Healthcare, Qiming Venture PartnersCo-Winner: Vor Bio Accepted by: Jianmin Fang, CEO, RemeGen (Vor Bio's leading project is from RemeGen) Presenter: Cyber Cao, Managing Director, HSGDeal of the Year — TiedCo-Winner: Hengrui Pharma – GSK Accepted by: Shelley Liu, Head of China Business Development &amp; Strategy, Hengrui; and Ming Fang, PhD, Senior Director, Search &amp; Evaluation, Business Development, GSK Presenter: Steve Yang, Co-Founder, the BayHelix Group; Co-CEO, WuXi ApptecCo-Winner: Innovent – Takeda Accepted by: Sophy Wang, Board Secretary &amp; Global BD, Innovent; and Eric Yeung, Head of Oncology and Global Business Development, Takeda Presenter: Kevin Yuan, CEO, Hankang CapitalAbout CHIC 2026The China Healthcare Investment Conference (CHIC) is a premier platform connecting innovation and investment in China's healthcare sector. Now in its 12th year, CHIC brings together senior decision-makers including venture capital and private equity investors, pharmaceutical executives, and biotech and medtech CEOs. The 2026 conference was held on March 23–24 at The Ritz-Carlton Hotel Pudong, Shanghai, under the theme &#34;Innovation in Healthcare – The Answer to Uncertainty.&#34;About the Gala Dinner Co-HostsWilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company's life cycle — from early-stage intellectual property strategy and patent prosecution to complex technology transactions, licensing, collaborations, as well as M&amp;As, IPOs and capital market offerings. As Founding Platinum Sponsor of CHIC, Wilson Sonsini has been a steadfast partner in the conference's mission to connect healthcare innovation with global capital.The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix serves as a co-host of the CHIC Gala Dinner and is a longstanding partner in advancing the global development of China's healthcare sector.CHIC 2026 Founding Individuals &amp; Organizing Committee / Working GroupThe following individuals served as the voting body for the CHIC 2026 Awards, representing the CHIC Founding Individuals and the Organizing Committee &amp; Working Group.FoundersMarietta Wu, Managing Director, Quan Capital Frank Kung, Managing Partner, Vivo Capital Hongbo Lu, Managing Member, NEXTBio Capital James Li, Venture Partner, Frazier Lifesciences Norman Chen, CEO, The Asian American Foundation2026 Organizing Committee &amp; Working GroupCyber Cao, Managing Director, HSG Jialing Dai, President &amp; Publisher, PharmaDJ Tess Cameron, Managing Director, RA Capital Management Kan Chen, Co-Head of Healthcare, Qiming Venture Partners Sean Zhang, Executive Director, Vivo Capital Dandan Dong, Venture Partner, TCGX Anna Chen, Partner, Frazier Life Sciences Yuan Yuan, Head of Platform Development, China, NEXTBio Capita Zhanghang Yan, Vice President, Quan Capital Yun Gao, Principal, Lilly Asia VenturesSOURCE PharmaDJ<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAxJk5ld3NJdGVtSWQ9Q04yNDcwOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDEyMDAwUFJfTkVXU19VU1BSX19fX19DTjI0NzA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAxJk5ld3NJdGVtSWQ9Q04yNDcwOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDEyMDAwUFJfTkVXU19VU1BSX19fX19DTjI0NzA4"/></div> </div></div>

159849

588130

516500

516820

517110

510660

589720

600276

159837

The 12th Annual China Healthcare Investment Conference (CHIC 2026) celebrated outstanding achievements in healthcare investment at its Awards Gala Dinner in Shanghai. The event recognized key players in the sector, awarding Insilico Medicine for IPO of the Year, and Kailera Therapeutics and Vor Bio for Private Financing of the Year. Hengrui Pharma-GSK and Innovent-Takeda shared the Deal of the Year award. The conference connects innovation and investment in China's healthcare, featuring leaders from venture capital, private equity, and the pharmaceutical industry.

20:00 ETCHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala